Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure

Journal of Hypertension

Volumn 19, Issue 10, 2001, Pages 1905-1912

  Sakata, Yasushi ^a   Yamamoto, Kazuhiro ^a   Masuyama, Tohru ^a   Mano, Toshiaki ^a   Nishikawa, Nagahiro ^a   Kuzuya, Tsunehiko ^a   Miwa, Takeshi ^b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiotensin; Fibrosis; Heart failure; Hypertension; Natriuretic peptides

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN HEXETIL; DOXAZOSIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HISTOLOGY; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

EID: 0034810877     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200110000-00027     Document Type: Article

References (21)

1. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
2. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
3. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognositic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
4. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
5. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload
6. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure
7. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: Absence of AT1 receptor downregulation and 'overdrive' of endothelin system
8. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: Different characteristics from renin angiotensin system-independent hypertrophy
9. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats
10. Development of different phenotypes of hypertensive heart failure systolic versus diastolic failure in Dahl salt-sensitive rats
11. Evolving Changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy
12. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
13. Cardiac fibrosis in mice lacking brain natriuretic peptide
14. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
15. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1
16. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
17. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes
18. Humoral factor(s) produced by pressure overload enhances cardiac hypertrophy and natriuretic peptide expression
19. Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibitor after myocardial infarction
20. Effects of angiotensin-converting enzyme inhibition on plasma brain natriuretic peptide levels in patients with heart failure
21. Brain natriuretic peptide as a novel cardiac hormone in humans